Pharmacology of the peptidomimetic, MEN 11149, a new potent, selective and orally effective tachykinin NK1 receptor antagonist

European Journal of Pharmacology

Volumn 341, Issue 2-3, 1998, Pages 201-209

  Cirillo, Rocco ^a   Astolfi, Mara ^a   Conte, Bruno ^a   Lopez, Giuseppe ^a   Parlani, Massimo ^a   Terracciano, Rosa ^b   Fincham, Christopher I ^b   Manzini, Stefano ^a  

^a Menarini Ricerche Via Tito Speri 10   (Italy)

^b Chemistry Department   (Italy)

Author keywords

Substance P; Tachykinin; Tachykinin NK1 receptor antagonist

Indexed keywords

2 (2 NAPHTHYL) 1 N [2 N (1H INDOL 3 YLCARBONYL)AMINOCYCLOHEXANECARBONYL] 1 [N' METHYL N' (4 METHYLPHENYLACETYL)]DIAMINOETHANE; DEVAPAMIL; MEN 10627; N BENZYL N2 [4 HYDROXY 1 [(1 METHYL 1H INDOL 3 YL)CARBONYL]PROLYL] N METHYL 3 (2 NAPHTHYL)ALANINAMIDE; NEUROKININ 1 RECEPTOR ANTAGONIST; NEUROKININ A; PLASMA PROTEIN; SAREDUTANT; SENKTIDE; SUBSTANCE P; TACHYKININ; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRONCHOSPASM; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG MECHANISM; GUINEA PIG; ILEUM; INFLAMMATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANIMALS; BLOOD PROTEINS; BRONCHOCONSTRICTION; GUINEA PIGS; HUMANS; ILEUM; INDOLES; ION CHANNELS; MALE; MUSCLE CONTRACTION; NAPHTHALENES; RECEPTORS, TACHYKININ; SUBSTANCE P; TACHYKININS; TUMOR CELLS, CULTURED;

EID: 0032509712     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)01453-2     Document Type: Article

References (35)

1. 1 antagonists: Prospects for the treatment of migraine headache. Can. J. Physiol. Pharmacol. 73:1995;871-877.
2. 1 receptor antagonist. Br. J. Pharmacol. 116:1995;3149-3157.
3. 1 receptor-selective neurokinin receptor antagonist with potent in vivo pharmacological effects: S18523. Eur. J. Pharmacol. 310:1996;37-46.
4. Cuello A.C., Ribeiro-da-Silva A., Ma W., Dekoninck Y., Henry J.L. Organization of substance P primary sensory neurons: Ultrastructural and physiological correlates. Reg. Pept. 46:1993;155-164.
5. 1 receptors and smoke-induced protein extravasation in relation to its cardiovascular effects. Eur. J. Pharmacol. 222:1992;213-218.
6. Dickinson K.E.J., Cohen R.B., Skwish S., Delane C.L., Serafino R.P., Poss M.A., Gu Z., Ryono D.E., Moreland S., Powell J.R. BMS 180560, an insurmountable inhibitor of angiotensin II-stimulated responses: Comparison with losartan and EXP3174. Br. J. Pharmacol. 113:1994;179-189.
7. 1 receptor antagonist. Eur. J. Pharmacol. 250:1993;403-413.
8. 1 receptor antagonist. FK 888. Br. J. Pharmacol. 107:1992;785-789.
9. 1 receptor antagonist, GR205171. Br. J. Pharmacol. 118:1996;78P.
10. Gitter B.D., Bruns R.D., Howbert J.J., Waters D.C., Threlkeld P.G., Cox L.M., Nixon J.A., Lobb K.L., Mason N.R., Stengel P.W., Cockerman S.L., Silbaugh S.A., Gehlert D.R., Schober D.A., Iyengar S., Calligaro D.O., Regoli D., Hipskind P.A. Pharmacological characterization of LY303870: A novel, potent and selective nonpeptide substance P (neurokinin-1) receptor antagonist. J. Pharmacol. Exp. Ther. 275:1995;737-744.
11. 1 receptors in human IM9 and U373 MG cells, using antagonist (FK888, (+)-CP-96,345, and RP 67580) binding. Eur. J. Pharmacol. 254:1994;221-227.
12. 2 receptor Eur. J. Pharmacol. 294:1995;239-245.
13. 1 receptor antagonist. Br. J. Pharmacol. 102:1991;168P.
14. Hagiwara D., Miyake H., Morimoto H., Murai M., Fujii T., Matsuo M. Studies of neurokinin antagonists. 1. The design of novel tripeptides possessing the glutaminyl-D-tryptophylphenylalanine sequence as substance P antagonists. J. Med. Chem. 35:1992;2015-2025.
15. 2-[((4R)-4-hydroxy-1-[(methyl-1H-indol-3-yl)carbonyl]-L-propyl]-N- methyl-N-(phenyl methyl)-3-(2-naphthyl)-L-alaninamide and its related compounds. J. Med. Chem. 37:1994;2090-2099.
16. Hashimoto M., Hayashi K., Murai M., Fujii T., Nishikawa M., Kiyoto S., Okuhara M., Kohsaka M., Imanaka H. WS9326A, a novel tachykinin antagonist isolated from streptomyces violaceusinger no.9326. II. Biological and pharmacological properties of WS9326A and tetrahydro-WS9326A (FK224). J. Antibiotics. 45:1992;1064.
17. Jancso N., Jancso-Gabor A., Szolcsanyi J. The role of sensory nerve endings in neurogenic inflammation induced in human skin and in the eye and paw of the rat. Br. J. Pharmacol. 32:1968;32-41.
18. Kenakin, T.P., 1987. Drug antagonism. In: Kenekin, T.P. (Ed.), Pharmacological Analysis of Drug-Receptor Interaction. Raven Press, New York, NY, pp. 205-244.
19. Lowe J.A. III, McLean S. Tachykinin antagonists. Curr. Pharm. Des. 1:1995;269-278.
20. Maggi C.A. The mammalian tachykinin receptors. Gen. Pharmacol. 26:1995;911-944.
21. Maggi C.A., Patacchini R., Rovero P., Giachetti A. Tachykinin receptors and tachykinin receptor antagonists. J. Autonom. Pharmacol. 13:1993;958-962.
22. 1 receptor. J. Pharmacol. Exp. Ther. 277:1996;900-908.
23. 1 receptor selectivity. Br. J. Pharmacol. 106:1992;123-126.
24. Munson P.J., Rodbard D. LIGAND: A versatile computerized approach for the characterization of ligand-binding systems. Anal. Biochem. 107:1980;220-239.
25. Olins G.M., Chen S.T., McMahon E.G., Palomo M.A., Reitz D.B. Elucidation of the insurmountable nature of an angiotensin receptor antagonist, SC-54629. Mol. Pharmacol. 47:1995;115-120.
26. Otsuka M., Yoshioka K. Neurotransmitter functions of mammalian tachykinins. Physiol. Rev. 73:1993;229-307.
27. Regoli D., Boudon A., Fauchere J.-L. Receptors and antagonists for substance P and related peptides. Pharmacol. Rev. 46:1994;551-597.
28. 3 binding sites in rat and guinea pig cortical membranes by the selective ligand [3H]senktide. Neuropeptides. 18:1991;107-114.
29. Reynolds I.J., Snowman A.D., Snyder S.H. (-)-[3H]Desmethoxyverapamil labels multiple calcium channel modulator receptors in brain and skeletal muscle membranes: Differentiation by temperature and dihydropyridines. J. Pharmacol. Exp. Ther. 237:1986;731-738.
30. 2+ channels. Eur. J. Pharmacol. 215:1992;351-352.
31. 1 tachykinin receptor antagonists: The use of cycloalkyl amino acids as a template. Biopolymers. 36:1994;511-524.
32. 1) receptor. Science. 251:1991;435-437.
33. Wienen W., Haauel N., Van Meel J.C.A., Narr B., Ries U., Entzeroth M. Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist. BIBR 277. Br. J. Pharmacol. 110:1993;245-252.
34. Wong P.C., Price W.A., Chiu A.T., Duncia J.V., Carini D.J., Wexler R.R., Johnson A.L., Timmermans P.B.M.W.M. Nonpeptide angiotensin II receptor antagonists. VIII. Characterization of functional antagonism displayed by DuP 753, an orally active antihypertensive agent. J. Pharmacol. Exp. Ther. 252:1990;719-725.
35. Wong P.C., Price W.A. Jr., Chiu A.T., Duncia J.V., Carini D.J., Wexler R.R., Johnson A.L., Timmermans P.B.M.W.M. Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: An active metabolite of DuP 753, an orally active antihypertensive agent. J. Pharmacol. Exp. Ther. 255:1990;211-217.